ロード中...
The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
Triple negative breast cancer (TNBC) is an aggressive subtype that accounts for 15-20% of cases, with a higher incidence of relapse/death. Even with adjuvant chemotherapy, the 5 year distant metastasis-free survival rate remains low. A total of 452 tumor registry patients with TNBC and no evidence o...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5762543/ https://ncbi.nlm.nih.gov/pubmed/29348858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22521 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|